Core Viewpoint - The company announced that senior management personnel Niu Zhanqi plans to reduce his shareholding due to personal funding needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections - **Share Reduction Details** - Niu Zhanqi intends to reduce his holdings by up to 87,500 shares, which represents 25% of his total shares and 0.22% of the company's total share capital [1] - The reduction period is set from September 18, 2025, to December 17, 2025 [1] - The shares to be sold are from the company's 2023 restricted stock incentive plan that has had its restrictions lifted [1]

Group 1 - The stock price of Kangchen Pharmaceutical closed at 50.65 yuan on August 26, 2025, down by 2.30 yuan, representing a decline of 4.34% from the previous trading day [1] - The trading volume on that day was 240 million yuan, with a turnover rate of 2.97% [1] - Kangchen Pharmaceutical's main business includes the research, production, and sales of innovative drugs, covering areas such as anti-tumor and hematological diseases [1] Group 2 - The company is part of concept sectors including biopharmaceuticals, innovative drugs, and specialized new products [1] - On August 27, 2025, Kangchen Pharmaceutical will hold its second extraordinary general meeting to review proposals for changes in registered capital and amendments to the company’s articles of association [1] - On August 26, 2025, there was a net outflow of 30.71 million yuan in main funds, with a cumulative net outflow of 137 million yuan over the past five days [1]

Group 1 - The innovative drug sector in the A-share market has experienced a decline, with several companies showing significant drops in stock prices [1] - Yuan Dong Biological fell over 8%, while Sunshine Nuohe dropped over 6%, and other companies like Haitai Biological and Guangshantang saw declines exceeding 5% [1] - The overall trend indicates a challenging environment for the innovative drug sector, as multiple companies are facing downward pressure on their stock performance [1] Group 2 - Specific stock performance data shows Yuan Dong Biological at -8.86% with a market capitalization of 11.4 billion, and Sunshine Nuohe at -6.99% with a market cap of 8.334 billion [2] - Other notable declines include Haitai Biological at -5.87% (7.32 billion), Guangshantang at -5.49% (22.9 billion), and Yifang Biological at -4.88% (23.2 billion) [2] - Year-to-date performance reveals that despite recent declines, some companies like Guangshantang and Aong Likang have shown substantial increases of 339.58% and 304.97% respectively [2]

Group 1 - The innovative drug sector in the A-share market has experienced a decline [1] - Yuan Dong Biological has dropped over 8% [1] - Sunshine Novo has decreased by more than 6% [1] Group 2 - Hai Te Biological and Guangsheng Tang have both fallen over 5% [1] - Yi Fang Biological, Li Fang Pharmaceutical, Kang Chen Pharmaceutical, Ang Li Kang, and Ou Lin Biological have all seen declines of over 4% [1]

Core Points - The company approved the use of up to RMB 300 million of idle raised funds for cash management, valid for 12 months from the board's approval date [1] - The company has redeemed principal and investment income from previously purchased capital-protected products, returning the funds to the designated account [1]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-041 北京康辰药业股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京康辰药业股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召 开的第四届董事会第十三次会议、第四届监事会第十一次会议审议通过《关于使 用闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币 3 亿元 的闲置募集资金适时进行现金管理，该额度自公司董事会审议通过之日起 12 个 月内有效，并在有效期内可循环滚动使用。具体内容详见公司于 2024 年 10 月 30 日在上海证券交易所网站及指定信息披露媒体披露的《康辰药业关于使用闲 置募集资金进行现金管理的公告》（公告编号：临 2024-065）。 截至本公告披露日，公司使用部分闲置募集资金购买的保本型产品已赎回， 募集资金本金及理财收益已归还至募集资金账户，具体情况如下： 特此公告。 北京康辰药业股份有限公司董事会 2025 年 8 月 23 日 单位： ...

Group 1 - The stock price of Kangchen Pharmaceutical is reported at 53.57 yuan, down by 0.42 yuan or 0.78% from the previous trading day [1] - The stock reached a high of 55.09 yuan and a low of 53.34 yuan during the trading session, with a total transaction volume of 1.87 billion yuan [1] - Kangchen Pharmaceutical operates in the biopharmaceutical sector, focusing on the research and development of innovative drugs [1] Group 2 - The company has recently completed the enrollment of the first subject in the Phase I clinical trial for its self-developed drug KC1086, which is a small molecule inhibitor of lysine acetyltransferase 6, intended for the treatment of advanced solid tumors [1] - On August 21, the net inflow of main funds was 54.18 million yuan, while the net outflow over the past five days amounted to 1.48 billion yuan [1]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has successfully completed the enrollment of the first subject in the Phase I clinical study (KC1086-I-01) evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of KC1086 for the treatment of advanced recurrent or metastatic solid tumors [1] Group 1 - KC1086 is a small molecule inhibitor with a novel structure that selectively targets Lysine Acetyltransferase 6 (KAT6) [1] - The drug is entirely developed by Beijing Kangchen Pharmaceutical Co., Ltd. [1] - The clinical study aims to assess the drug's potential in treating advanced recurrent or metastatic solid tumors [1]

Core Viewpoint - The company has successfully initiated the first subject enrollment for the Phase I clinical study of KC1086, a novel small molecule inhibitor targeting KAT6, aimed at treating advanced recurrent or metastatic solid tumors [1] Group 1 - The company announced the completion of the first subject enrollment for the clinical study titled "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KC1086 in Patients with Advanced Recurrent or Metastatic Solid Tumors" [1] - KC1086 is characterized as a potent and highly selective small molecule inhibitor of lysine acetyltransferase 6 (KAT6) [1] - The intended use of KC1086 is for the treatment of advanced recurrent or metastatic solid tumors [1]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-040 北京康辰药业股份有限公司 关于 KC1086 完成 I 期临床试验首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京康辰药业股份有限公司（以下简称"公司"）自主研发的 KC1086 片（简称"KC1086"），顺利完成"评价 KC1086 治疗晚期复发或转移性实体瘤 的安全性、耐受性、药代动力学和初步有效性的 I 期临床研究（KC1086-I-01）" 首例受试者入组。现将有关情况公告如下： 一、KC1086 治疗晚期复发或转移性实体瘤的 I 期临床研究相关情况 公司于 2025 年 6 月 30 日收到国家药品监督管理局核准签发的临床试验通 知书后，随即开展 KC1086 项目的 I 期临床试验。该试验采取多中心、开放、单 臂试验设计，旨在评价 KC1086 在晚期复发或转移性实体瘤受试者中的安全性和 耐受性，确定最大耐受剂量（MTD）和Ⅱ期试验推荐剂量（RP2D）。于近日， 该试验已在首研单位中国医学科学院肿瘤医院完成 ...